Substituted heterocyclic ethers and their use in CNS disorders

• US 8,026,257 B2
• Filed: 07/01/2008
• Issued: 09/27/2011
• Est. Priority Date: 07/11/2007
• Status: Active Grant

• Current Assignee: Bristol-Myers Squibb Company
• Original Assignee: Bristol-Myers Squibb Company
• Inventors: Denhart, Derek J., Degnan, Andrew P., Tora, George O., Macor, John E., Vrudhula, Vivekananda M., Bronson, Joanne J.
• Primary Examiner(s): Kosack; Joseph
• Assistant Examiner(s): COUGHLIN, MATTHEW P
• Application Number:
  US12/165,967
• Publication Number:
  US 20090018132A1
• Time in Patent Office: 1,183 Days
• Field of Search: 514/322, 514/323, 514/234.5, 546/199, 546/201, 544/129
• US Class Current: 514/322
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/22 Anxiolytics
• CPC Class Codes: A61P 25/24 Antidepressants
• CPC Class Codes: A61P 25/32 Alcohol-abuse
• CPC Class Codes: A61P 3/00 Drugs for disorders of the metabolism of the blood or the extracellular fluid A61P7/00
• CPC Class Codes: C07D 401/12 linked by a chain containing hetero atoms as chain links

Abstract

The invention encompasses compounds of Formula I, including pharmaceutically acceptable salts, their pharmaceutical compositions, and their use in treating CNS disorders.

Claims

1. A compound of Formula I

2. A compound of claim 1 where R² is hydrogen or alkyl and Ar² is indolyl, indazolyl, benzimidazolyl, or benzotriazolyl and Ar² is substituted with 0-3 substituents selected from the group consisting of halo, alkyl, cycloalkyl, (cycloalkyl)alkyl, haloalkyl, hydroxy, alkoxy, haloalkoxy, cyano, amino, alkylamino, dialkylamino, pyrrolidinyl, piperidinyl, piperazinyl, (alkyl)piperazinyl, morpholinyl, thiomorpholinyl, and Ar³.

3. A compound of claim 1 where R¹ is hydrogen or methyl.

4. A compound of claim 1 where R² is hydrogen and R³ is hydrogen.

5. A compound of claim 1 where R² is methyl and R³ is hydrogen.

6. A compound of claim 1 where Ar¹ is phenyl or monohalophenyl.

7. A compound of claim 1 where Ar² is indazolyl and is substituted with 0-3 substituents selected from the group consisting of halo, alkyl, cycloalkyl, (cycloalkyl)alkyl, haloalkyl, cyanoalkyl, hydroxy, alkoxy, haloalkoxy, cyano, amino, alkylamino, dialkylamino, pyrrolidinyl, piperidinyl, piperazinyl, (alkyl)piperazinyl, morpholinyl, thiomorpholinyl, and Ar³.

8. A compound of claim 1 selected from the group consisting of

7-Methyl-5-(((4-phenylpiperidin-4-yl)methoxy)methyl)-1H-indazole;

5-Bromo-7-(((4-phenylpiperidin-4-yl)methoxy)methyl)-1H-indazole;

4-(7-(((4-Phenylpiperidin-4-yl)methoxy)methyl)-1H-indazol-5-yl)benzonitrile;

4-(1-Methyl-7-(((4-phenylpiperidin-4-yl)methoxy)methyl)-1H-indazol-5-yl)benzonitrile;

4-(2-Methyl-7-(((4-phenylpiperidin-4-yl)methoxy)methyl)-2H-indazol-5-yl)benzonitrile;

5-Methyl-7-(((4-phenylpiperidin-4-yl)methoxy)methyl)-1H-indazole;

1,5-Dimethyl-7-(((4-phenylpiperidin-4-yl)methoxy)methyl)-1H-indazole;

2,5-Dimethyl-7-(((4-phenylpiperidin-4-yl)methoxy)methyl)-2H-indazole;

7-(((4-Phenylpiperidin-4-yl)methoxy)methyl)-5-(trifluoromethyl)-1H-indazole;

7-(((1-Methyl-4-phenylpiperidin-4-yl)methoxy)methyl)-5-(trifluoromethyl)-1H-indazole;

1-Methyl-7-(((4-phenylpiperidin-4-yl)methoxy)methyl)-5-(trifluoromethyl)-1H-indazole;

2-Methyl-7-(((4-phenylpiperidin-4-yl)methoxy)methyl)-5-(trifluoromethyl)-2H-indazole;

1-Methyl-7-(((1-methyl-4-phenylpiperidin-4-yl)methoxy)methyl)-5-(trifluoromethyl)-1H-indazole;

2-Methyl-7-(((1-methyl-4-phenylpiperidin-4-yl)methoxy)methyl)-5-(trifluoromethyl)-2H-indazole;

7-(((4-(4-Fluorophenyl)piperidin-4-yl)methoxy)methyl)-5-(trifuoromethyl)-1H-indazole;

7-(((4-(4-Fluorophenyl)-1-methylpiperidin-4-yl)methoxy)methyl)-5-(trifluoromethyl)-1H-indazole;

7-(((4-(4-Fluorophenyl)piperidin-4-yl)methoxy)methyl)-1-methyl-5-(trifluoromethyl)-1H-indazole;

7-(((4-(4-Fluorophenyl)piperidin-4-yl)methoxy)methyl)-2-methyl-5-(trifluoromethyl)-2H-indazole;

7-(((4-(4-Fluorophenyl)-1-methylpiperidin-4-yl)methoxy)methyl)-1-methyl-5-(trifluoromethyl)-1H-indazole;

(±

)-7-(1-((4-Phenylpiperidin-4-yl)methoxy)ethyl)-5-(trifluoromethyl)-1H-indazole;

(±

)-7-(1-((1-Methyl-4-phenylpiperidin-4-yl)methoxy)ethyl)-5-(trifluoromethyl)-1H-indazole;

7-(1-((4-(4-Fluorophenyl)piperidin-4-yl)methoxy)ethyl)-5-(trifuoromethyl)-1H-indazole;

7-(1-((4-(4-Fluorophenyl)-1-methylpiperidin-4-yl)methoxy)ethyl)-5-(trifluoromethyl)-1H-indazole;

7-(1-((4-(4-Fluorophenyl)piperidin-4-yl)methoxy)ethyl)-1-methyl-5-(trifluoromethyl)-1H-indazole;

7-(1-((4-(4-Fluorophenyl)-1-methylpiperidin-4-yl)methoxy)ethyl)-1-methyl-5-(trifluoromethyl)-1H-indazole;

7-(1-((4-(4-Fluorophenyl)-1-methylpiperidin-4-yl)methoxy)ethyl)-2-methyl-5-(trifluoromethyl)-2H-indazole;

7-(((4-Phenylpiperidin-4-yl)methoxy)methyl)-1H-indazole;

3-Cyclopropyl-7-(((4-phenylpiperidin-4-yl)methoxy)methyl)-5-(trifluoromethyl)-1H-indazole;

3-Bromo-7-(((4-phenylpiperidin-4-yl)methoxy)methyl)-5-(trifluoromethyl)-1H-indazole;

3-Methyl-7-(((4-phenylpiperidin-4-yl)methoxy)methyl)-5-(trifluoromethyl)-1H-indazole;

(±

)-5-Chloro-7-(1-((4-phenylpiperidin-4-yl)methoxy)ethyl)-1H-indazole;

(±

)-5-Chloro-7-(1-((1-methyl-4-phenylpiperidin-4-yl)methoxy)ethyl)-1H-indazole;

(±

)-5-Chloro-1-methyl-7-(1-((4-phenylpiperidin-4-yl)methoxy)ethyl)-1H-indazole;

(±

)-5-Chloro-2-methyl-7-(1-((4-phenylpiperidin-4-yl)methoxy)ethyl)-2H-indazole;

(±

)-3-Methyl-7-(1-((4-phenylpiperidin-4-yl)methoxy)ethyl)-5-(trifluoromethyl)-1H-indazole;

(±

)-3-Methyl-7-(1-((1-methyl-4-phenylpiperidin-4-yl)methoxy)ethyl)-5-(trifluoromethyl)-1H-indazole;

5-Cyclopropyl-7-(((4-phenylpiperidin-4-yl)methoxy)methyl)-1H-indazole;

(±

)-5-Bromo-7-(1-((4-(4-fluorophenyl)-1-methylpiperidin-4-yl)methoxy)ethyl)-1H-indazole;

(±

)-5-Cyclopropyl-7-(1-((4-(4-fluorophenyl)-1-methylpiperidin-4-yl)methoxy)ethyl)-1H-indazole;

(±

)-7-(1-((4-(4-Fluorophenyl)-1-methylpiperidin-4-yl)methoxy)ethyl)-1H-indazole-5-carbonitrile;

(±

)-7-(1-((4-(4-Fluorophenyl)-1-methylpiperidin-4-yl)methoxy)ethyl)-5-methyl-1H-indazole;

(±

)-4-7-(1-((4-(4-Fluorophenyl)-1-methylpiperidin-4-yl)methoxy)ethyl)-1H-indazole-5-yl)morpholino;

7-(1-((4-(4-Fluorophenyl)-1-methylpiperidin-4-yl)methoxy)ethyl)-N,N-dimethyl-1H-indazol-5-amine;

(±

)-7-(1-((4-(4-Fluorophenyl)-1-methylpiperidin-4-yl)methoxy)ethyl)-5-methoxy-1H-indazole;

(±

)-5-Fluoro-7-(1-((4-(4-fluorophenyl)-1-methylpiperidin-4-yl)methoxy)ethyl)-1H-indazole;

5-Cyclopropyl-7-(1-((4-(4-fluorophenyl)-1-methylpiperidin-4-yl)methoxy)ethyl)-1H-indazole;

(±

)-5-Chloro-7-(1-((4-(4-fluorophenyl)-1-methylpiperidin-4-yl)methoxy)ethyl)-3-methyl-1H-indazole;

(±

)-5-Chloro-3-cyclopropyl-7-(1-((4-(4-fluorophenyl)-1-methylpiperidin-4-yl)methoxy)ethyl)-1H-indazole;

(±

)-3-Bromo-5-chloro-7-(1-((4-(4-fluorophenyl)-1-methylpiperidin-4-yl)methoxy)ethyl)-1H-indazole;

(±

)-5-Chloro-2-cyclopropyl-7-(1-((4-(4-fluorophenyl)-1-methylpiperidin-4-yl)methoxy)ethyl)-2H-indazole;

(±

)-3,5-Dichloro-7-(1-((4-(4-fluorophenyl)-1-methylpiperidin-4-yl)methoxy)ethyl)-1H-indazole;

(±

)-1-(2,2-Difluoroethyl)-7-(1-((4-(4-fluorophenyl)-1-methylpiperidin-4-yl)methoxy)ethyl)-5-methyl-1H-indazole;

(±

)-2-(2,2-Difluoroethyl)-7-(1-((4-(4-fluorophenyl)-1-methylpiperidin-4-yl)methoxy)ethyl)-5-methyl-2H-indazole;

(±

)-1-(Cyclopropylmethyl)-7-(1-((4-(4-fluorophenyl)-1-methylpiperidin-4-yl)methoxy)ethyl)-5-methyl-1H-indazole;

(±

)-2-(Cyclopropylmethyl)-7-(1-((4-(4-fluorophenyl)-1-methylpiperidin-4-yl)methoxy)ethyl)-5-methyl-2H-indazole;

(±

)-1-Cyclopropyl-7-(1-((4-(4-fluorophenyl)-1-methylpiperidin-4-yl)methoxy)ethyl)-5-methyl-1H-indazole;

4-(1-Cyclopropyl-7-(((1-methyl-4-phenylpiperidin-4-yl)methoxy)methyl)-1H-indazol-5-yl)benzonitrile;

7-(((1-Methyl-4-phenylpiperidin-4-yl)methoxy)methyl)-5-(trifluoromethyl)-1H-indole;

1-Methyl-7-(((1-methyl-4-phenylpiperidin-4-yl)methoxy)methyl)-5-(trifluoromethyl)-1H-indole;

7-(((1-Methyl-4-(4-fluorophenyl)piperidin-4-yl)methoxy)methyl)-5-(trifluoromethyl)-1H-indole;

1-Methyl-7-(((1-methyl-4-(4-fluorophenyl)piperidin-4-yl)methoxy)methyl)-5-(trifluoromethyl)-1H-indole;

(±

)-7-(1-((1-Methyl-4-phenylpiperidin-4-yl)methoxy)ethyl)-5-(trifluoromethyl)-1H-indole;

(±

)-1-Methyl-7-(1-((1-methyl-4-phenylpiperidin-4-yl)methoxy)ethyl)-5-(trifluoromethyl)-1H-indole;

(±

)-7-(1-((4-(4-Fluorophenyl)-1-methylpiperidin-4-yl)methoxy)ethyl)-5-(trifluoromethyl)-1H-indole;

(±

)-7-(1-((4-(4-Fluorophenyl)-1-methylpiperidin-4-yl)methoxy)ethyl)-1-methyl-5-(trifluoromethyl)-1H-indole;

7-(1-((4-(4-Fluorophenyl)-1-methylpiperidin-4-yl)methoxy)ethyl)-1-methyl-5-(trifluoromethyl)-1H-indole;

4-(((1-Methyl-4-phenylpiperidin-4-yl)methoxy)methyl)-6-(trifluoromethyl)-1H-indole 2,2,2-trifluoroacetate;

1-Methyl-4-(((1-methyl-4-phenylpiperidin-4-yl)methoxy)methyl)-6-(trifluoromethyl)-1H-indole 2,2,2-trifluoroacetate;

7-(((4-(4-Fluorophenyl)-1-methylpiperidin-4-yl)methoxy)methyl)-1-methyl-5-(trifluoromethyl)-1H-benzo[d][1,2,3]triazole;

4-(((4-(4-Fluorophenyl)-1-methylpiperidin-4-yl)methoxy)methyl)-2-methyl-6-(trifluoromethyl)-2H-benzo[d][1,2,3]triazole;

4-(((4-(4-Fluorophenyl)-1-methylpiperidin-4-yl)methoxy)methyl)-1-methyl-6-(trifluoromethyl)-1H-benzo[d][1,2,3]triazole;

4-(1-(Cyclopropylmethyl)-2-(((1-methyl-4-phenylpiperidin-4-yl)methoxy)methyl)-1H-benzo[d]imidazol-5-yl)benzonitrile;

5-Bromo-1-(cyclopropylmethyl)-2-(((1-methyl-4-phenylpiperidin-4-yl)methoxy)methyl)-1H-benzo[d]imidazole;

6-Bromo-1-(cyclopropylmethyl)-2-(((1-methyl-4-phenylpiperidin-4-yl)methoxy)methyl)-1H-benzo[d]imidazole;

1-(Cyclopropylmethyl)-5-(2,4-dichlorophenyl)-2-(((1-methyl-4-phenylpiperidin-4-yl)methoxy)methyl)-1H-benzo[d]imidazole;

6-Cyclopropyl-1-(cyclopropylmethyl)-2-(((1-methyl-4-phenylpiperidin-4-yl)methoxy)methyl)-1H-benzo[d]imidazole;

1-(Cyclopropylmethyl)-2-(((1-methyl-4-phenylpiperidin-4-yl)methoxy)methyl)-5-(trifluoromethyl)-1H-benzo[d]imidazole;

1-(Cyclopropylmethyl)-2-(((1-methyl-4-phenylpiperidin-4-yl)methoxy)methyl)-6-(trifluoromethyl)-1H-benzo[d]imidazole; and

4-(((1-Methyl-4-phenylpiperidin-4-yl)methoxy)methyl)-6-(trifluoromethyl)-1H-benzo[d]imidazole;

or a pharmaceutically acceptable salt thereof.

9. A compound of claim 1 selected from the group consisting of

Methyl 2-(5-chloro-1H-indazol-7-yl)-2-((4-(4-fluorophenyl)-1-methylpiperidin-4-yl)methoxy)acetate trifluoroacetic acid salt;

2-(5-Chloro-1H-indazol-7-yl)-2-((4-(4-fluorophenyl)-1-methylpiperidin-4-yl)methoxy)acetic acid trifluoroacetic acid salt;

2-(5-Chloro-1H-indazol-7-yl)-2-((4-(4-fluorophenyl)-1-methylpiperidin-4-yl)methoxy)-N,N-dimethylacetamide trifluoroacetic acid salt;

2-(5-Chloro-1H-indazol-7-yl)-2-((4-(4-fluorophenyl)-1-methylpiperidin-4-yl)methoxy)ethanol trifluoroacetic acid salt;

5-Chloro-7-(1-((4-(4-fluorophenyl)-1-methylpiperidin-4-yl)methoxy)-2-methoxyethyl)-1H-indazole trifluoroacetic acid salt;

5-Chloro-7-(2-fluoro-1-((4-(4-fluorophenyl)-1-methylpiperidin-4-yl)methoxy)ethyl)-1H-indazole;

2-(5-Chloro-1H-indazol-7-yl)-2-((4-(4-fluorophenyl)-1-methylpiperidin-4-yl)methoxy)acetonitrile;

6-Chloro-4-(1-((4-(4-fluorophenyl)-1-methylpiperidin-4-yl)methoxy)ethyl)-1H-benzo[d]imidazol-2(3H)-one trifluoroacetic acid salt;

5-Chloro-7-(1-((4-(4-fluorophenyl)-1-methylpiperidin-4-yl)methoxy)ethyl)-1-methyl-1H-benzo[d]imidazol-2(3H)-one trifluoroacetic acid salt;

6-Chloro-4-(1-((4-(4-fluorophenyl)-1-methylpiperidin-4-yl)methoxy)ethyl)-1-methyl-1H-benzo[d]imidazol-2(3H)-one trifluoroacetic acid salt;

(R)-3,5-Dichloro-7-(1-((4-(4-fluorophenyl)piperidin-4-yl)methoxy)ethyl)-1H-indazole;

(R)-3,5-Dichloro-7-(1-((4-(4-fluorophenyl)-1-methylpiperidin-4-yl)methoxy)ethyl)-1H-indazole;

(R)-3,5-Dibromo-7-(1-((4-(4-fluorophenyl)piperidin-4-yl)methoxy)ethyl)-1H-indazole;

(R)-3,5-Dibromo-7-(1-((4-(4-fluorophenyl)-1-methylpiperidin-4-yl)methoxy)ethyl)-1H-indazole;

(R)-5-Chloro-7-(1-((4-(4-fluorophenyl)-1-methylpiperidin-4-yl)methoxy)ethyl)-3-methyl-1H-indazole;

(R)-5-chloro-2-(cyclopropylmethyl)-7-((1-(4-fluorophenyl)piperidin-4-yl)methoxy)ethyl)-2H-indazole;

(R)-5-chloro-2-(cyclopropylmethyl)-7-(1-((4-(4-fluorophenyl)-1methylpiperidin-4-yl)methoxy)ethyl)-2H-indazole;

(R)-5-chloro-1-(cyclopropylmethyl)-7-(1-((4-(4-fluorophenyl)-1methylpiperidin-4-yl)methoxy)ethyl)-1H-indazole;

(R)-2-(5-chloro-7-(1-((4-(4-fluorophenyl)-1-methylpiperidine-4-yl)methoxy)ethyl)-2H-indazole-2-yl)acetonitrile;

(R)-2-(5-chloro-7-(1-((4-(4-fluorophenyl)-1-methylpiperidine-4-yl)methoxy)ethyl)-1H-indazole-2-yl)acetonitrile;

(S)-3,5-dichloro-7-(2-fluoro-1-((4-(4-fluorophenyl)-1-methylpiperidine-4-yl)methoxy)ethyl)-1H-indazole;

3-(5-chloro-1H-indazol-7-yl)-3-((4-(4-fluorophenyl)-1-methylpiperidine-4-yl)methoxy)propanenitrile;

2-(5-chloro-1H-indazol-7-yl)-2-((4-(4-fluorophenyl)piperidine-4-yl)methoxy)-N,N-dimethylethanamine;

2-(5-chloro-1H-indazol-7-yl)-2-((4-(4-fluorophenyl)-1-methylpiperidine-4-yl)methoxy)-N,N-dimethylethanamine;

5-chloro-7(2,2-difluoro-1-((4-(4-fluorophenyl)-1-methylpiperidin-4-yl)methoxy)ethyl)-1H-indazole;

5-chloro-7-(1-((4-(4-fluorophenyl)piperidin-4-yl)methoxy)propyl)-1H-indazole;

5-chloro-7-(1-((4-(4-fluorophenyl)-1-methylpiperidin-4-yl)methoxy)propyl)-1H-indazole;

(R)-3,5-dichloro-7-(1-((4-(4-fluorophenyl-1-methyl)piperidine-4-yl)methoxy)ethyl)-2-(2,2,2-trifluoroethyl)-2H-indazole;

(R)-3,5-dichloro-7-(1-((4-(4-fluorophenyl-1-methyl)piperidine-4-yl)methoxy)ethyl)-2-(2,2,2-trifluoroethyl)-1H-indazole;

(R)-3-bromo-5-chloro-7-(1-((1-methyl-4-phenylpiperidin-4yl)methoxy)ethyl)-1H-indazole;

(R)-3,5-dichloro-7-(1-((4-phenylpiperidin-4yl)methoxy)ethyl)-1H-indazole;

(R)-3,5-dichloro-7-(1-((1-methyl-4-phenylpiperidin-4yl)methoxy)ethyl)-1H-indazole;

(S)-3,5-dichloro-7-(1-((4-(4-fluorophenyl)piperidin-4-yl)methoxy)ethyl)-1h-indazole;

(S)-3,5-dichloro-7-(1-((4-(4-fluorophenyl)-1-methylpiperidin-4-yl)methoxy)ethyl)-1h-indazole;

(±

)-7-(1-((4-(4-fluorophenyl)-1-methylpiperidin-4-yl)methoxy)ethyl)-5-(trifluoromethyl)indolin-2-one;

(±

)-5-chloro-7-(1-((4-(4-fluorophenyl)-1-methylpiperidin-4-yl)methoxy)ethyl)-1H-indole-3-carbonitrile;

7-(1-((4-(4-fluorophenyl)-1-methylpiperidin-4-yl)methoxy)ethyl)-1,3-dimethyl-5-(trifluoromethyl)-1H-indole;

(±

)-7-(1-((4-(4-fluorophenyl)-1-methylpiperidin-4-yl)methoxy)ethyl)-3-methyl-5-(trifluoromethyl)-1H-indole;

(±

)-4-(1-((4-(4-fluorophenyl)-1-methylpiperidin-4-yl)methoxy)ethyl)-1-methyl-6-(trifluoromethyl)-1H-indole;

(±

)-4-(1-((4-(4-fluorophenyl)-1-methylpiperidin-4-yl)methoxy)ethyl)-6-(trifluoromethyl)-1H-indole;

(±

)-4-(1-((4-(4-fluorophenyl)piperidin-4-yl)methoxy)ethyl)-6-(trifluoromethyl)indolin-2-one, TFA;

(R)-6-bromo-1-(cyclopropylmethyl)-4-(1-((1-methyl-4-phenylpiperidin-4-yl)methoxy)ethyl)-1H-benzo[d]imidazole;

(S)-6-bromo-1-(cyclopropylmethyl)-4-(1-((1-methyl-4-phenylpiperidin-4-yl)methoxy)ethyl)-1H-benzo[d]imidazole;

(S)-6-bromo-3-(cyclopropylmethyl)-4-(1-((4-phenylpiperidin-4-yl)methoxy)ethyl)-1H-benzo[d]imidazole;

(S)-1-(Cyclopropylmethyl)-4-(1-((4-(4-fluorophenyl)-1-methylpiperidin-4-yl)methoxy)ethyl)-6-(trifluoromethyl)-1H-benzo[d]imidazole;

(R)-1-(cyclopropylmethyl)-4-(1-((4-(4-fluorophenyl)-1-methylpiperidin-4-yl)methoxy)ethyl)-6-(trifluoromethyl)-1H-benzo[d]imidazole;

(S)-1-(Cyclopropylmethyl)-4-(1-((4-(4-fluorophenyl)-1-methylpiperidin-4-yl)methoxy)ethyl)-6-(trifluoromethyl)-1H-benzo[d]imidazole;

(R)-1-(cyclopropylmethyl)-4-(1-((4-(4-fluorophenyl)-1-methylpiperidin-4-yl)methoxy)ethyl)-6-(trifluoromethyl)-1H-benzo[d]imidazole;

(S)-1-Ethyl-4-(1-((1-methyl-4-phenylpiperidin-4-yl)methoxy)ethyl)-6-(trifluoromethyl)-1H-benzo[d]imidazole; and

(R)-1-ethyl-4-(1-((1-methyl-4-phenylpiperidin-4-yl)methoxy)ethyl)-6-(trifluoromethyl)-1H-benzo[d]imidazole;

or a pharmaceutically acceptable salt thereof.

10. The compound of claim 1 that is

11. The compound of claim 10 where the salt is the hydrochloride.

12. A composition comprising a pharmaceutically acceptable amount of a compound of claim 1 and a pharmaceutically acceptable carrier.

13. The composition of claim 12 where the compound is

14. A method for treating a disorder associated with aberrant levels of tachykinins or serotonin comprising administering an effective amount of a compound of claim 1 to a patient afflicted with the disorder wherein the disorder is anxiety, depression, obsessive compulsive disorder, bulimia, panic disorder, post-traumatic stress disorder, alcohol dependence, or urinary incontinence.

15. The method of claim 14 where the disorder is anxiety.

16. The method of claim 14 where the disorder is depression, obsessive compulsive disorder, bulimia, panic disorder, post-traumatic stress disorder, alcohol dependence, or urinary incontinence.

17. The method of claim 14 where the compound is